This pilot study was designed to further evaluate the diagnostic performance of 68 Ga-PSMA-617 PET/CT in ACC in a head-to-head comparison with18F-FDG PET/CT and to preliminarily assess the safety of and therapeutic response to PSMA RLT in patients with ACC. This evidence concerns the gene FOLH1 and adrenal cortex carcinoma.